Page last updated: 2024-11-13

destruxin e

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

destruxin E: cyclodepsipeptide from entomopathogenic fungus Metarhyzium anisopliae; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID46934590
CHEBI ID188838
MeSH IDM0120385

Synonyms (13)

Synonym
destruxin e
destruxin de
76689-14-0
(3r,10s,13s,16s,19s)-16-[(2s)-butan-2-yl]-10,11,14-trimethyl-3-[[(2s)-oxiran-2-yl]methyl]-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone
CHEBI:188838
y168ewu66t ,
e-destruxin
unii-y168ewu66t
cyclo(n-methyl-l-alanyl-.beta.-alanyl-4,5-anhydro-3-deoxy-d-erythro-pentonoyl-l-prolyl-l-isoleucyl-n-methyl-l-valyl)
sb-242539
destruxin e, (-)-
Q27294124
GLXC-26433

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" charged radicals (COO-) appear the least toxic probably because they do not penetrate easily the cellular membranes."( Insecticidal and cytotoxic effects of natural and hemisynthetic destruxins.
Dumas, C; Pais, M; Quiot, JM; Robert, P; Vey, A, 1994
)
0.29
" Evaluation of the cytotoxic activity of these different compounds suggested that a wide range of metabolites with synergistic or adverse effects are present in the crude extract."( Toxicity testing of destruxins and crude extracts from the insect-pathogenic fungus Metarhizium anisopliae.
Butt, TM; Skrobek, A, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclodepsipeptideA depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.86)18.7374
1990's14 (40.00)18.2507
2000's11 (31.43)29.6817
2010's9 (25.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.66 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index5.64 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]